Blab Business
Tempus AI to Acquire Personalis in $16.25-Per-Share Deal to Expand MRD Testing and Biopharma Data Capabilities
Tempus AI Inc. (NASDAQ: TEM) announced it will purchase all outstanding shares of Personalis Inc. (PSNL) that it does not already own for $16.25 a share. The offer, a 6 % premium to Personalis’ Friday close and a 28 % premium to its 30‑day volume‑weighted average, is structured as 100 % stock with an option to add up to 50 % cash. Personalis shareholders will receive a floating exchange ratio of Tempus common stock, capped at 0.3356 shares per Personalis share. The parties expect the transaction to close in late 2026 or early 2027.
The purchase is aimed at bolstering Tempus’ foothold in minimal residual disease (MRD) testing—a fast‑growing oncology diagnostic niche that uses liquid biopsy to spot the tiniest traces of cancer cells after treatment. Personalis’ NeXT Personal assay, which monitors 1,800 variants in tumor tissue, has already driven a 38 % quarter‑over‑quarter rise in volumes. Tempus said that the assay’s adoption should accelerate as more sales representatives receive training and additional indications secure reimbursement.
During a call with analysts, a Tempus executive identified as Eric explained that the company is “quickly gaining market adoption” in the MRD space. He added that Tempus plans to embed more of its technology into the MRD offering over time, including hospital connectivity, AI‑enabled ordering tools and AI‑derived insights. The company also highlighted that the acquisition would broaden its precision‑medicine strategy, adding AI‑enabled tools, hospital connectivity and biopharma opportunities while maintaining its goal of being adjusted EBITDA and free‑cash‑flow positive in 2027.
Founded in 2015 by Eric Lefkofsky in Chicago, Tempus launched its precision‑medicine platform in 2016 and went public on the Nasdaq in June 2024. The company has built a portfolio of AI‑driven diagnostics for oncology, cardiology, radiology and depression, and has pursued several strategic acquisitions to expand its data and analytics capabilities.
Personalis, headquartered in San Diego, focuses on cancer diagnostics and genomic profiling. Its NeXT Personal liquid‑biopsy test has been highlighted in clinical studies, including a phase‑3 trial with AstraZeneca, and has received attention for its sensitivity in detecting minimal residual disease.
The deal is expected to be financed with a combination of Tempus’ cash on hand and additional borrowing that may be secured between signing and closing. The transaction’s structure allows Tempus to maintain a strong balance sheet while acquiring a company that complements its existing AI and data analytics strengths.
Analysts note that the acquisition could position Tempus to capture a larger share of the MRD market, which is projected to grow as reimbursement frameworks expand and as clinicians adopt liquid‑biopsy testing for monitoring cancer recurrence. The NeXT Personal assay’s performance and the company’s rapid volume growth suggest that the integration could accelerate Tempus’ precision‑medicine roadmap.
The announcement comes at a time when the precision‑medicine sector is attracting significant investment. While the acquisition price is modest relative to Personalis’ market capitalization, the premium reflects Tempus’ confidence in the strategic fit and the potential for synergies in data, AI and clinical adoption.
As the deal moves toward closing, both companies will need to complete regulatory approvals and satisfy any antitrust or securities requirements. The transaction is expected to close in late 2026 or early 2027, at which point Personalis shareholders will receive the agreed exchange ratio of Tempus stock.
In summary, Tempus’ acquisition of Personalis is a strategic move to deepen its MRD testing capabilities and expand its biopharma data platform. The deal aligns with Tempus’ broader precision‑medicine strategy and positions the company to benefit from the growing demand for liquid‑biopsy diagnostics and AI‑enabled clinical tools.
The purchase is aimed at bolstering Tempus’ foothold in minimal residual disease (MRD) testing—a fast‑growing oncology diagnostic niche that uses liquid biopsy to spot the tiniest traces of cancer cells after treatment. Personalis’ NeXT Personal assay, which monitors 1,800 variants in tumor tissue, has already driven a 38 % quarter‑over‑quarter rise in volumes. Tempus said that the assay’s adoption should accelerate as more sales representatives receive training and additional indications secure reimbursement.
During a call with analysts, a Tempus executive identified as Eric explained that the company is “quickly gaining market adoption” in the MRD space. He added that Tempus plans to embed more of its technology into the MRD offering over time, including hospital connectivity, AI‑enabled ordering tools and AI‑derived insights. The company also highlighted that the acquisition would broaden its precision‑medicine strategy, adding AI‑enabled tools, hospital connectivity and biopharma opportunities while maintaining its goal of being adjusted EBITDA and free‑cash‑flow positive in 2027.
Founded in 2015 by Eric Lefkofsky in Chicago, Tempus launched its precision‑medicine platform in 2016 and went public on the Nasdaq in June 2024. The company has built a portfolio of AI‑driven diagnostics for oncology, cardiology, radiology and depression, and has pursued several strategic acquisitions to expand its data and analytics capabilities.
Personalis, headquartered in San Diego, focuses on cancer diagnostics and genomic profiling. Its NeXT Personal liquid‑biopsy test has been highlighted in clinical studies, including a phase‑3 trial with AstraZeneca, and has received attention for its sensitivity in detecting minimal residual disease.
The deal is expected to be financed with a combination of Tempus’ cash on hand and additional borrowing that may be secured between signing and closing. The transaction’s structure allows Tempus to maintain a strong balance sheet while acquiring a company that complements its existing AI and data analytics strengths.
Analysts note that the acquisition could position Tempus to capture a larger share of the MRD market, which is projected to grow as reimbursement frameworks expand and as clinicians adopt liquid‑biopsy testing for monitoring cancer recurrence. The NeXT Personal assay’s performance and the company’s rapid volume growth suggest that the integration could accelerate Tempus’ precision‑medicine roadmap.
The announcement comes at a time when the precision‑medicine sector is attracting significant investment. While the acquisition price is modest relative to Personalis’ market capitalization, the premium reflects Tempus’ confidence in the strategic fit and the potential for synergies in data, AI and clinical adoption.
As the deal moves toward closing, both companies will need to complete regulatory approvals and satisfy any antitrust or securities requirements. The transaction is expected to close in late 2026 or early 2027, at which point Personalis shareholders will receive the agreed exchange ratio of Tempus stock.
In summary, Tempus’ acquisition of Personalis is a strategic move to deepen its MRD testing capabilities and expand its biopharma data platform. The deal aligns with Tempus’ broader precision‑medicine strategy and positions the company to benefit from the growing demand for liquid‑biopsy diagnostics and AI‑enabled clinical tools.
